Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Study of Anti-T Lymphocyte Globulin (ATLG) in GVHD Prophylaxis

NCT06525519 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06525519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06525519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Study of Anti-T Lymphocyte Globulin (ATLG) in GVHD Prophylaxis
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2024
Completion date
July 31, 2026
Enrollment
104 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplantation